Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Byers, 2015, Small cell lung cancer: where do we go from here?, Cancer, 121, 664, 10.1002/cncr.29098 Hanna, 2006, Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer, J Clin Oncol, 24, 2038, 10.1200/JCO.2005.04.8595 Puglisi, 2010, Treatment options for small cell lung cancer—do we have more choice?, Br J Cancer, 102, 629, 10.1038/sj.bjc.6605527 Zatloukal, 2010, A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease, Ann Oncol, 21, 1810, 10.1093/annonc/mdq036 Schmittel, 2011, A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer, Ann Oncol, 22, 1798, 10.1093/annonc/mdq652 Asai, 2014, Relapsed small cell lung cancer: treatment options and latest developments, Ther Adv Med Oncol, 6, 69, 10.1177/1758834013517413 Von Pawel, 2014, Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer, J Clin Oncol, 32, 4012, 10.1200/JCO.2013.54.5392 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 2016 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, 364, 2517, 10.1056/NEJMoa1104621 Curran, 2010, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, Proc Natl Acad Sci USA, 107, 4275, 10.1073/pnas.0915174107 Hammers, 2015, Expanded cohort results from CheckMate 016: a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC), J Clin Oncol, 33, 4516, 10.1200/jco.2015.33.15_suppl.4516 Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, 373, 23, 10.1056/NEJMoa1504030 Rizvi, 2015, Safety and efficacy of first-line nivolumab (NIVO; anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC), J Thoracic Oncol, 10, S176 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, 369, 122, 10.1056/NEJMoa1302369 Postow, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N Engl J Med, 372, 2006, 10.1056/NEJMoa1414428 2015 Agrawal, 2015, Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy, J Immunother Cancer, 3, P141, 10.1186/2051-1426-3-S2-P141 Phillips, 2015, Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer, Appl Immunohistochem Mol Morphol, 23, 541, 10.1097/PAI.0000000000000256 Simon, 1989, Optimal two-stage designs for phase II clinical trials, Control Clin Trials, 10, 1, 10.1016/0197-2456(89)90015-9 Loochtan, 2015, Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer, Muscle Nerve, 52, 307, 10.1002/mus.24648 Pietanza, 2012, Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker, Clin Cancer Res, 18, 1138, 10.1158/1078-0432.CCR-11-2059 Rudin, 2015, A DLL3-targeted ADC, rovalpituzumab tesirine, demonstrates substantial activity in a phase I study in relapsed and refractory SCLC, J Thoracic Oncol, 10, S192 Wang, 2013, Histologic assessment of tumor-associated CD45(+) cell numbers is an independent predictor of prognosis in small cell lung cancer, Chest, 143, 146, 10.1378/chest.12-0681 Buchbinder, 2015, CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition, Am J Clin Oncol, 39, 98, 10.1097/COC.0000000000000239 Ott, 2015, Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028, J Clin Oncol, 33, 7502, 10.1200/jco.2015.33.15_suppl.7502 Royal, 2010, Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma, J Immunother, 33, 828, 10.1097/CJI.0b013e3181eec14c Maur, 2012, Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma, J Clin Oncol, 30, e76, 10.1200/JCO.2011.38.7886 Boyd, 2015, Ipilimumab induced encephalitis: a case report, Immunome Res, 11, 092 Johnson, 2015, Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma, J Clin Oncol, 33, e122, 10.1200/JCO.2013.51.1683 Liao, 2014, Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma, Neuro Oncol, 16, 589, 10.1093/neuonc/nou001 Shirai, 2016, Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma, Jpn J Clin Oncol, 46, 86, 10.1093/jjco/hyv158